{"classes":[{"categories":[{"measurements":[{"comment":"Due to a lack of events the upper limit was not reached.","groupId":"OG000","lowerLimit":"4.7","upperLimit":"NA","value":"8.6"},{"comment":"Due to a lack of events the upper limit was not reached.","groupId":"OG001","lowerLimit":"3.1","upperLimit":"NA","value":"10.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"description":"The distribution of survival time will be estimated using the method of Kaplan-Meier. The comparison of overall survival between two treatment arms will be based on the log-rank test.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may cross over to Group II at the time of disease progression.","id":"OG000","title":"Group I (Nivolumab)"},{"description":"Patients receive varlilumab IV over 90 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Group II (Varlilumab, Nivolumab)"}],"paramType":"MEDIAN","populationDescription":"All eligible and treated patients.","reportingStatus":"POSTED","timeFrame":"37 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}